Nektar Therapeutics (NKTR) PT Lowered to $41 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $38.61 -1.45%
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Join SI Premium – FREE
BMO Capital analyst George Farmer lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $41.00 (from $75.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bright Horizons (BFAM) PT Lowered to $75 at BMO Capital
- Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
- Ambev (ABEV3:BZ) (ABEV) PT Lowered to BRL16.60 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
